Medtronic (NYSE:MDT) said today that it won CE Mark approval in the European Union for the SureTune2 software used with its deep-brain stimulation devices.
The software is designed to allow physicians to fine-tune patients’ therapy “by visualizing patient-specific information in one comprehensive view including anatomy, physiology, and calculated stimulation field,” the Fridley, Minn.-based company said.
“Medtronic is committed to providing advanced technology to the multidisciplinary teams who are helping DBS patients, and I’m convinced that SureTune will provide them with easy-to-use tools to aid in optimizing therapy outcomes,” brain modulation general manager Lothar Krinke said in prepared remarks. “SureTune is a key aspect of Medtronic’s commitment to providing integrated solutions for improving accuracy and confidence from surgery to post-operative DBS patient management.”
“SureTune will have an important impact on the care of patients with deep brain stimulation because it allows me for the first time to visualize activation patterns of DBS within the individual segmented patient anatomy,” added Dr. Jens Volkmann of the University Clinic of Würzburg, Germany. “It simplifies the trial and error process associated with DBS programming by helping me identify the best contacts, which saves me time.”
The FDA has not approved SureTune2 software for the U.S. market.
The post MDT wins CE Mark for SureTune2 DBS software appeared first on MassDevice.
from MassDevice http://ift.tt/2aGgDQS
Cap comentari:
Publica un comentari a l'entrada